ES2157957T3 - Procedimientos para inhibir la endometriosis. - Google Patents

Procedimientos para inhibir la endometriosis.

Info

Publication number
ES2157957T3
ES2157957T3 ES94307528T ES94307528T ES2157957T3 ES 2157957 T3 ES2157957 T3 ES 2157957T3 ES 94307528 T ES94307528 T ES 94307528T ES 94307528 T ES94307528 T ES 94307528T ES 2157957 T3 ES2157957 T3 ES 2157957T3
Authority
ES
Spain
Prior art keywords
chem
procedures
endometriosis
inhibit
inhibit endometriosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94307528T
Other languages
English (en)
Inventor
Larry John Black
George Joseph Cullinan
Michael William Draper
Charles David Jones
David Edward Seyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2157957T3 publication Critical patent/ES2157957T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)

Abstract

UN METODO PARA INHIBIR ENDOMETRIOSIS QUE COMPRENDE ADMINISTRAR A UN HUMANO CON NECESIDAD DE TRATAMIENTO UNA CANTIDAD EFECTIVA DE UN COMPUESTO QUE TIENE LA FORMULA (I) EN DONDE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, -CH3, -CO-ALQUILO(C1-C6), O -CO-AR, EN DONDE AR ES FENILO OPCIONALMENTE SUSTITUIDO; R2 SE SELECCIONA DEL GRUPO COMPUESTO DE PIRROLIDINA Y PIPERIDINO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE SOLUBLE DEL MISMO.
ES94307528T 1993-10-15 1994-10-13 Procedimientos para inhibir la endometriosis. Expired - Lifetime ES2157957T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/138,643 US5461065A (en) 1993-10-15 1993-10-15 Methods for inhibiting endometriosis

Publications (1)

Publication Number Publication Date
ES2157957T3 true ES2157957T3 (es) 2001-09-01

Family

ID=22482966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94307528T Expired - Lifetime ES2157957T3 (es) 1993-10-15 1994-10-13 Procedimientos para inhibir la endometriosis.

Country Status (25)

Country Link
US (2) US5461065A (es)
EP (1) EP0652005B1 (es)
JP (1) JPH07188014A (es)
KR (1) KR950010893A (es)
CN (1) CN1049335C (es)
AT (1) ATE203404T1 (es)
AU (1) AU677700B2 (es)
CA (1) CA2118092A1 (es)
CZ (1) CZ287246B6 (es)
DE (1) DE69427800T2 (es)
DK (1) DK0652005T3 (es)
ES (1) ES2157957T3 (es)
GR (1) GR3036971T3 (es)
HU (1) HUT71235A (es)
IL (1) IL111284A (es)
NO (1) NO311242B1 (es)
NZ (1) NZ264677A (es)
PH (1) PH31261A (es)
PT (1) PT652005E (es)
RU (1) RU2157203C2 (es)
SG (1) SG43319A1 (es)
SI (1) SI0652005T1 (es)
TW (1) TW296382B (es)
UA (1) UA26930C2 (es)
ZA (1) ZA948029B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
IL115018A0 (en) * 1994-08-22 1995-12-08 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses
US5554600A (en) * 1995-01-20 1996-09-10 Eli Lilly And Company Methods for inhibiting endometriosis
DE69600709T2 (de) * 1995-06-07 1999-03-18 Eli Lilly And Co., Indianapolis, Ind. Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen
KR970002795A (ko) 1995-10-30 1997-01-28 모리 하루오 네비게이션(navigation)장치
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU1180900A (en) * 1998-11-26 2000-06-13 Teikoku Hormone Mfg. Co., Ltd. Medicinal compositions for periodic administration
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
WO2002094268A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
WO2002094788A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
RU2005101635A (ru) * 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
KR101731008B1 (ko) 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
SE500453C2 (sv) * 1991-10-07 1994-06-27 Karobio Ab Ett in vitro förfarande för utvärdering av en substans effekter
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
NO943879L (no) 1995-04-18
HU9402959D0 (en) 1995-02-28
US5461065A (en) 1995-10-24
ZA948029B (en) 1996-04-15
US5693656A (en) 1997-12-02
IL111284A (en) 2000-02-29
CZ287246B6 (en) 2000-10-11
CZ253794A3 (en) 1995-05-17
EP0652005A1 (en) 1995-05-10
UA26930C2 (uk) 1999-12-29
JPH07188014A (ja) 1995-07-25
SG43319A1 (en) 1997-10-17
GR3036971T3 (en) 2002-01-31
EP0652005B1 (en) 2001-07-25
NZ264677A (en) 1997-07-27
TW296382B (es) 1997-01-21
AU677700B2 (en) 1997-05-01
PT652005E (pt) 2001-11-30
CN1049335C (zh) 2000-02-16
NO943879D0 (no) 1994-10-13
ATE203404T1 (de) 2001-08-15
SI0652005T1 (en) 2001-12-31
RU94036772A (ru) 1996-08-27
DE69427800T2 (de) 2001-12-06
HUT71235A (en) 1995-11-28
KR950010893A (ko) 1995-05-15
PH31261A (en) 1998-06-18
DK0652005T3 (da) 2001-09-24
AU7578794A (en) 1995-05-04
DE69427800D1 (de) 2001-08-30
CA2118092A1 (en) 1995-04-16
IL111284A0 (en) 1994-12-29
RU2157203C2 (ru) 2000-10-10
NO311242B1 (no) 2001-11-05
CN1107043A (zh) 1995-08-23

Similar Documents

Publication Publication Date Title
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
DK0664126T3 (da) Hæmning af trombin
ES2172525T3 (es) Inhibicion de la fibrosis uterina.
ATE150307T1 (de) Hemmung von seborrhoe und akne
ATE168887T1 (de) Hemmung von dysfunctionalen uterusblutungen
ZA948027B (en) Methods for inhibiting angiogenesis and angiogenic diseases
NO943873D0 (no) Hemming av bruskdegradering

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652005

Country of ref document: ES